Larimar Therapeutics, Inc. (LRMR): who owns it and who trades it
As of Nov 12, 2026, LRMR insiders reported 14 purchases worth $26.1M in the last 12 months. The largest buyer was Deerfield Mgmt HIF, L.P. (Director), with $25M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Larimar Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns LRMR
162 funds and institutions reported LRMR shares worth $292M at the end of Q2 2026, about 92% of the company. The largest holder is Deerfield Management Company, L.P. with 34.3%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Deerfield Management Company, L.P. | 35.61M | 34.28% | $109M | No change |
| Blue Owl Capital Holdings LP | 9.16M | 8.82% | $27.9M | +29% |
| BlackRock, Inc. | 5.68M | 5.47% | $17.3M | +51% |
| Defilade Capital Management, L.P. | 3.67M | 3.53% | $11.2M | – |
| Driehaus Capital Management LLC | 3.16M | 3.05% | $9.6M | +8% |
| Vanguard Capital Management LLC | 2.97M | 2.86% | $9.1M | +4% |
| Rtw Investments, LP | 2.57M | 2.47% | $7.8M | +71% |
| AQR Capital Management LLC | 2.37M | 2.28% | $7.2M | +190% |
| Marshall Wace, LLP | 2.01M | 1.94% | $6.1M | +116% |
| DAFNA Capital Management LLC | 2.01M | 1.93% | $6.1M | -1% |
| Goldman Sachs Group Inc | 1.75M | 1.69% | $5.3M | +12% |
| Geode Capital Management, LLC | 1.68M | 1.62% | $5.1M | +51% |
| Qube Research & Technologies Ltd | 1.64M | 1.58% | $5M | +94% |
| Citadel Advisors LLC | 1.46M | 1.40% | $4.4M | +181% |
| State Street Corp | 1.41M | 1.36% | $4.3M | +55% |
| Vanguard Portfolio Management LLC | 1.40M | 1.35% | $4.3M | +245% |
| Woodline Partners LP | 1.40M | 1.35% | $4.3M | No change |
| Millennium Management LLC | 1.33M | 1.28% | $4.1M | -63% |
| Dimensional Fund Advisors LP | 961,083 | 0.93% | $2.9M | +20% |
| FMR LLC (Fidelity) | 937,368 | 0.90% | $2.9M | +1375% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, LRMR insiders reported $26.1M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Thomas Edward Hamilton | Director | Purchase | 70,000 | $2.67 | $187K | Form 4 |
| Nov 11, 2026 | Carole Ben-Maimon | CEO | Purchase | 18,050 | $2.77 | $50K | Form 4 |
| Nov 11, 2026 | Michael Celano | CFO | Purchase | 18,460 | $2.71 | $50K | Form 4 |
| Nov 11, 2026 | John B. Harlow Jr. | President | Purchase | 17,800 | $2.80 | $49.9K | Form 4 |
| Nov 11, 2026 | Gopi Shankar | Chief Development Office | Purchase | 5,000 | $2.71 | $13.5K | Form 4 |
| Nov 11, 2026 | Joseph Truitt | Director | Purchase | 3,500 | $2.80 | $9.8K | Form 4 |
| Nov 11, 2026 | Frank E Thomas | Director | Purchase | 8,000 | $2.73 | $21.8K | Form 4 |
| Jul 6, 2026 | Thomas Edward Hamilton | Director | Purchase | 50,000 | $3.34 | $167K | Form 4 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. +9 | Director | Purchase | 1.08M | $5.00 | $5.4M | Form 4 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. +9 | Director | Purchase | 2.00M | $5.00 | $10M | Form 4 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. +9 | Director | Purchase | 831,978 | $5.00 | $4.2M | Form 4 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. +9 | Director | Purchase | 1.08M | $5.00 | $5.4M | Form 4 |
| Feb 27, 2026 | Thomas Edward Hamilton | Director | Purchase | 100,000 | $5.00 | $500K | Form 4 |
| Feb 27, 2026 | Frank E Thomas | Director | Purchase | 5,000 | $5.00 | $25K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Deerfield Mgmt HIF, L.P. | Director, 10% owner | $25M | – | Feb 27, 2026 |
| Thomas Edward Hamilton | Director | $854K | – | Nov 12, 2026 |
| Michael Celano | Chief Financial Officer | $50K | – | Nov 11, 2026 |
| Carole Ben-Maimon | President and CEO, Director | $50K | – | Nov 11, 2026 |
| John B. Harlow Jr. | President and COO | $49.9K | – | Nov 11, 2026 |
| Frank E Thomas | Director | $46.8K | – | Nov 11, 2026 |
| Gopi Shankar | Chief Development Officer | $13.5K | – | Nov 11, 2026 |
| Joseph Truitt | Director | $9.8K | – | Nov 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LRMR short interest
High short interest. 10.1% of LRMR shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 21%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.54M LRMR shares were sold short, 10.1% of the shares outstanding, down 28.1% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 8.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.54M | 10.14% | -28% | 1.28M | 8.2 |
| Oct 15, 2026 | 14.66M | 14.11% | -5% | 1.64M | 8.9 |
| Sep 30, 2026 | 15.37M | 14.80% | +11% | 1.77M | 8.7 |
| Sep 15, 2026 | 13.89M | 13.37% | +1% | 932,915 | 14.9 |
| Aug 31, 2026 | 13.72M | 13.21% | +2% | 895,151 | 15.3 |
| Aug 14, 2026 | 13.44M | 12.94% | +10% | 1.20M | 11.2 |
| Jul 31, 2026 | 12.19M | 11.73% | +8% | 1.30M | 9.4 |
| Jul 15, 2026 | 11.30M | 10.88% | -7% | 2.31M | 4.9 |
| Jun 30, 2026 | 12.19M | 11.74% | +16% | 3.84M | 3.2 |
| Jun 15, 2026 | 10.54M | 10.14% | +31% | 2.08M | 5.1 |
| May 29, 2026 | 8.05M | 7.75% | -8% | 1.52M | 5.3 |
| May 15, 2026 | 8.74M | 8.42% | +5% | 2.03M | 4.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Larimar Therapeutics company events
Larimar Therapeutics filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementThe Company issued a press release announcing that the Company completed its rolling Biologics License Application submission to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich’s ataxia. Filing
- Sep 29, 2026LeadershipThe Board of Directors of Larimar Therapeutics, Inc. appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow, effective as of September 29, 2026. Filing
- Aug 4, 2026AnnouncementThe Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
- Jun 29, 2026AnnouncementLarimar Therapeutics, Inc. issued a press release announcing (i) that it has submitted the first module of the Company’s rolling Biologics License Application submission to the Food and Drug Administration for accelerated approval of nomlabofusp and (ii) positive data from the Company’s ongoing… Filing
- May 19, 2026VoteReported shareholder vote results. Filing
- May 14, 2026AnnouncementThe Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementMade another announcement. Filing
- Feb 27, 2026AgreementSigned an important agreement. Filing
- Feb 24, 2026AnnouncementMade another announcement. Filing
- Jan 22, 2026SharesSold new shares outside a public offering. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 17, 2025SharesSold new shares outside a public offering. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Larimar Therapeutics financials
Famous investors that hold LRMR
4 of the 50 well-known investors we track reported holding LRMR in their latest 13F filing. The largest position is Ken Griffin's, worth $4.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q2 2026 | 1.46M | $4.4M | 0.0% | +181% |
| Israel Englander · Millennium Management | Q2 2026 | 1.33M | $4.1M | 0.0% | -63% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 184,043 | $588K | 0.0% | -38% |
| Steve Cohen · Point72 Asset Management | Q2 2026 | 134,806 | $411K | 0.0% | -87% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Larimar Therapeutics, Inc. (LRMR) stock
Who owns the most LRMR stock?
The largest reported owner of Larimar Therapeutics, Inc. (LRMR) is Deerfield Management Company, L.P., with 34.3% of the company. In total, 162 funds and institutions reported holding LRMR at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are LRMR insiders buying or selling?
In the last 12 months, LRMR insiders reported 14 open-market purchases worth $26.1M and no sales. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in LRMR?
As of Oct 30, 2026, 10.54M LRMR shares were sold short, 10.1% of the shares outstanding, down 28.1% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 8.2 trading days (days to cover). See the history.
Which famous investors hold LRMR?
4 of the 50 well-known investors we track reported LRMR in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $4.4M. See all holders.
Executive pay
Larimar Therapeutics's chief executive was paid a total of $3.5M for the year ended Dec 31, 2025, up 40% from $2.5M the year before. In the last 12 months, Larimar Therapeutics's executives and directors bought $1.1M of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.